Management of osteoporosis with PTH: treatment and prescription patterns in Europe

References

• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. J Am Med Assoc 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Whitfield JF. Growing Bone, 2nd edn. Austin, TX: Landes Bioscience, 2007
   Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26 :688-703
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Hanley DA, Watson PH, et al. Parathyroid Hormone. San Diego: Academic Press, 2002
   Google Scholar
• Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932;16:547
   Google Scholar
• Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-12
   Google Scholar
• Tam CS, Heersche JN, Murray TM, et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982;110:506-12
   PubMed Web of Science ®Google Scholar
• Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of Parathyroid Hormone, Alendronate, or both in men with osteoporosis. N Engl J Med 2003;349 :1216-26
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146 :326-39
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88 :5212-20
   PubMed Web of Science ®Google Scholar
• Roux C, Illera-Martín O, Clausen J. Efficacy of PTH(1–84) on vertebral and non-vertebral fractures in postmenopausal women with a high risk of vertebral fractures. Calcif Tissue Int 2007;80 (Suppl. 1):S48
   Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of Parathyroid Hormone and Alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349:1207-15
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud K, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. New Engl J Med 2005;353:555-65
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Delmas P, Hosking D, et al. Sequential treatment with full-length parathyroid hormone PTH (1–84) of postmenopausal women with primary osteoporosis. Calcif Tissue Int 2007;80:S126
   Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporosis Int 2000;11:669-74
   PubMed Web of Science ®Google Scholar
• Melton III LJ, Atkinson EJ, O'Connor MK, et al. Bone density and fracture risk in men. J Bone Miner Res 1998; 13 :1915-23
   PubMed Web of Science ®Google Scholar
• Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10
   PubMed Web of Science ®Google Scholar
• Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol 2005;17:456-61
   PubMed Web of Science ®Google Scholar
• O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-8
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22 :465-74
   PubMed Web of Science ®Google Scholar
• EPOS Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002;17:716-24
   PubMed Web of Science ®Google Scholar
• Leidig-Bruckner G, Limberg B, Felsenberg D, et al. Sex difference in the validity of vertebral deformities as an index of prevalent vertebral osteoporotic fractures: a population survey of older men and women. Osteoporos Int 2000;11 :102-19
   PubMed Web of Science ®Google Scholar
• Naves M, Diaz-Lopez JB, Gomez C, et al. Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50. Osteoporos Int 2005;16 :2013-7
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Spector TD, Eyres KS, et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporosis Int 1993;3 :138-47
   PubMed Web of Science ®Google Scholar
• HAS. Commision de la transparence. Avis, 05 Juillet 2006
   Google Scholar
• Adachi JD, Ioannidis G, Olszynski WP, et al. The impact of incident vertebral and nonvertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord 2002;3:11
   PubMed Web of Science ®Google Scholar
• Hall SE, Criddle RA, Comito TL, et al. A case–control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporosis Int 1999;9:508-15
   PubMed Web of Science ®Google Scholar
• Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychological and social outcomes. Rheum Dis Clin North Am 2001;27:255
   PubMed Web of Science ®Google Scholar
• Robbins J, Hirsch C, Whitmer R, et al. The association of bone mineral density and depression in an older population. J Am Geriatr Soc 2001;49:732-6
   PubMed Web of Science ®Google Scholar
• Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fracture and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:821-8
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. J Am Med Assoc 2001;285:320-3
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39
   PubMed Web of Science ®Google Scholar
• Ismail AA, Cockerill W, Cooper C, et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study Osteoporosis Int 2001;12:85-90
   Google Scholar
• Cauley JA, Hochberg MC, Lui L-Y, et al. Long-term risk of incident vertebral fractures. J Am Med Assoc 2007;298 :2761-7
   PubMed Web of Science ®Google Scholar
• Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. J Epidemiol Community Health 1990;44:241-5
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles' or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-8
   PubMed Web of Science ®Google Scholar
• Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. Br Med J 1993;307:1248-50
   PubMed Web of Science ®Google Scholar
• Magaziner J, Simonsick EM, Kashner TM, et al. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 1990;45:M101-M7
   PubMedGoogle Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int 2005;16 :229-38
   PubMed Web of Science ®Google Scholar
• Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-12
   PubMed Web of Science ®Google Scholar
• Feldstein AC, Nichols GA, Elmer PJ, et al. Older women with fractures: patients falling through the cracks of guideline recommended osteoporosis screening and treatment. J Bone Joint Surg Am 2003;85:A2294-302
   PubMed Web of Science ®Google Scholar
• Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000;82:1063-70
   PubMedGoogle Scholar
• Harrington JT, Broy SB, Derosa AM, et al. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002;47:651-4
   PubMed Web of Science ®Google Scholar
• Kamel HK, Hussain MS, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000;109 :326-8
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004;180:S18-22
   PubMed Web of Science ®Google Scholar
• Dreinhöfer KE, Féron JM, Herrera A, et al. Orthopaedic surgeons and fragility fractures. A survey by the Bone and Joint Decade and the International Osteoporosis foundation. J Bone Joint Surg 2004;86:958-61
   PubMedGoogle Scholar
• Endres HG, Dasch B, Maier C, et al. Diagnosis and treatment of osteoporosis in postmenopausal women with distal radius fracture in Germany. Curr Med Res Opin 2007;23:2171-81
   PubMed Web of Science ®Google Scholar
• The European Union Osteoporosis Consultation Panel. Osteoporosis in the European Community: Action Plan. Brussels: European Commission, 2003
   Google Scholar
• Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998;57:378-9
   PubMed Web of Science ®Google Scholar
• Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment. The ICARO study. J Bone Miner Res 2006;21:1565-70
   PubMed Web of Science ®Google Scholar
• Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006;368:973-4
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-52
   PubMed Web of Science ®Google Scholar
• Bocuzzi SJ, Folz SH, Omar MA, et al. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporosis Int 2005;16 (Suppl. 3):OC10
   Google Scholar
• Cramer JA, Monkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15 :1003-8
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38 :922-8
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporosis Int 2006;17:1626-9
   PubMed Web of Science ®Google Scholar
• Saag K, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid induced osteoporosis. New Engl J Med 2007;357 :2028-39
   PubMed Web of Science ®Google Scholar